LRP1B and Familial prostate cancer: Recently, LRP1B mutation status was associated with improved patients’ outcome to immunotherapy, being described as a biomarker for ICIs in multiple cancers such as melanoma, non-small cell lung cancer, prostate cancer, and advanced biliary tract cancer [58,79,89,119].